Physician profile
Malgorzata Patro
NPI 1841516234
$2,753.70
in general payments reported to CMS, 2019-2025
14 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2021: $518 · 2022: $194 · 2023: $310 · 2024: $877 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503 · Education: $48.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.88 |
| Education | $48.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $797.05 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $351.54 | 2022-2025 | |
| Travere Therapeutics, INC. | $321.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.02 | 2024-2025 | Jardiance |
| Amgen INC. | $137.88 | 2024 | Krystexxa |
| Mallinckrodt Enterprises LLC | $124.28 | 2019 | |
| Ani Pharmaceuticals, INC. | $120.69 | 2023 | Purified Cortrophin Gel |
| Lilly USA, LLC | $118.63 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $117.90 | 2021 | |
| Aurinia Pharma U.S., INC. | $116.18 | 2023 | Lupkynis |
| Baxter Healthcare | $106.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $86.32 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $46.75 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $22.90 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malgorzata Patro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.